Collegium Pharmaceutical, Inc. Capital Expenditures Incurred but Not yet Paid
Collegium Pharmaceutical, Inc. (COLL) reported Capital Expenditures Incurred but Not yet Paid of $508.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $301.00K, a 142.74% increase year-over-year.
- Collegium Pharmaceutical, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $207.00K.
- Collegium Pharmaceutical, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $5.00K.
- Collegium Pharmaceutical, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $190.00K.
- Collegium Pharmaceutical, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $319.00K, a 72.43% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $185.00K, a 5.11% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $176.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $301.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $508.00K 10-Q · filed 2026-08-06 | $513.00K derived: sum of 3 quarters · filed 2026-08-06 | $703.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $207.00K 10-Q · filed 2026-05-07 | $212.00K derived: sum of 2 quarters · filed 2026-05-07 | $402.00K derived: sum of 3 quarters · filed 2026-05-07 | $526.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $195.00K derived: sum of 2 quarters · filed 2026-02-26 | $319.00K derived: sum of 3 quarters · filed 2026-08-06 | $319.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $190.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $314.00K derived: sum of 2 quarters · filed 2026-08-06 | $314.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $124.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $124.00K 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $185.00K 10-K · filed 2026-02-26 | |||
| 2024-06-30 | $200.00K 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $176.00K 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $53.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |